Clinical trial
Efficacy of Octreotide Treatment in Patients With Primary Inoperable Thymoma
NCT00332969 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00332969 |
|---|---|
| Title | Efficacy of Octreotide Treatment in Patients With Primary Inoperable Thymoma |
| Official title | Efficacy of Medical Treatment With Octreotide in Patients With Primary Inoperable Thymoma to Reduce Tumor Size |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Thymoma |
| Intervention type | Drug |
| Interventions | Octreotide |
| Enrollment | 25 |
| Start date | Sep 1, 2005 |
| Primary completion | Oct 1, 2010 |
| First posted | Jun 2, 2006 |
| Last update posted | Mar 31, 2017 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: